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ABSTRACT 
Glutamate and NPY have been implicated in hippocampal neuropathology in temporal lobe 
epilepsy. Thus, we investigated the involvement of NPY receptors in mediating neuroprotection 
against excitotoxic insults in organotypic cultures of rat hippocampal slices. Exposure of 
hippocampal slice cultures to 2 µM AMPA (α-amino-3-hydroxy-5-methyl-isoxazole-4-
propionate) induced neuronal degeneration, monitored by propidium iodide uptake, of granule 
cells and CA1 pyramidal cells. For dentate granule cells, selective activation of Y1, Y2, or Y5 
receptors with 1 µM [Leu31,Pro34]NPY, 300 nM NPY1336 or 1 µM 500 nM NPY(1923)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP, respectively, had a neuroprotective effect against 
AMPA, whereas only the activation of Y2 receptors was effective for CA1 pyramidal cells. 
When the slice cultures were exposed to 6 µM kainate, the CA3 pyramidal cells displayed 
significant degeneration, and in this case the activation of Y1, Y2, and Y5 receptors was 
neuroprotective. For the kainic acid-induced degeneration of CA1 pyramidal cells, it was again 
found that only the Y2 receptor activation was effective. Based on the present findings, it was 
concluded that Y1, Y2, and Y5 receptors effectively can modify glutamate receptor-mediated 
neurodegeneration in the hippocampus. 
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 Neuropeptide Y (NPY) is a 36-amino-acid peptide abundantly distributed in the brain and associated with a number of physiological and pathological conditions (1). This peptide has been shown to modulate anxiety, pain, memory, eating behavior, and many other 
functions in the central, as well as in the peripheral, nervous systems (1, 2). Another significant 
role of NPY that has become evident during the past decade is regulation of seizure activity (3). 
At least five NPY receptor subtypes have been identified based on different pharmacological 
profiles: Y1, Y2, Y4, Y5, and y6 (4). A putative Y3 receptor has also been identified (5). 
[Leu31,Pro34]NPY and NPY1336 have been proposed to be particularly selective agonists for 
 
  
Y1 and Y2 receptors, respectively (6). More recently, Cabrele et al. (7) developed the first Y5 
receptor-selective analog of NPY, [Ala31,Aib32]NPY. Also, there are currently several NPY 
receptor antagonists available: BIBP3226 binds and specially inhibits the Y1 receptor subtype 
(8), whereas BIIE0246 is a potent and selective Y2 receptor antagonist (9), and L-152,804 an Y5 
receptor antagonist (10). 
In the hippocampus, Y1 and Y2 receptors are highly expressed (11). Receptors of the Y1 subtype 
are preferentially located in granule cells of the dentate molecular layer, whereas Y2 receptors 
are expressed at high concentrations in the mossy fiber and Schaffer collateral fields (12). 
Moreover, Y5 receptor binding sites can also be found in the strata oriens and radiatum of the 
CA3 and CA1 areas (13, 14). Presently, there is evidence for the involvement of these three NPY 
receptors subtypes in epilepsy. The activation of Y2 receptors suppresses seizure activity in 
hippocampal slices in vitro (15) and in vivo models (3). In human temporal lobe epilepsy, 
significant alterations in Y1 and Y2 receptor binding were observed (16). NPY Y5 receptors also 
seem to be involved in the suppression of seizure activity (17, 18). In different animal models of 
epilepsy, NPY is highly expressed by granule cells and mossy fibers of the hippocampus (19, 
20), whereas in normal conditions only GABAergic interneurons express this peptide. 
Furthermore, knockout mice lacking the NPY gene develop spontaneous seizures and are more 
susceptible to pentylenetetrazol and kainic acid-induced motor seizures, which are inhibited by 
intracerebral infusion of NPY (21). Thus, these evidences suggest that NPY-mediated effects 
may be activated under epileptogenesis and excitotoxicity. 
One candidate mechanism for the anticonvulsant properties of NPY is the inhibition of calcium 
influx (22, 23) and glutamate release (24, 23). However, in spite of the relevance of the field, the 
relation between NPY and glutamate is not fully understood. In the present study, we 
demonstrate that activation of Y1, Y2, and Y5 receptors can protect against excitotoxic 
glutamate receptor mediated neurodegeneration in organotypic slice cultures of the rat 
hippocampus. 
MATERIAL AND METHODS 
Organotypic hippocampal slice cultures 
Organotypic hippocampal slice cultures were prepared according to the interface method (25), as 
modified by Kristensen et al. (26) and Noraberg et al. (27). In brief, after decapitation and 
removal of the brains of 7-day old Wistar rat pups (Møllegaard, Denmark), the hippocampi were 
isolated and the middorsal parts sectioned into 350-µm-thick slices on a McIlwain tissue 
chopper. The tissue slices were placed in cold Gey´s balanced salt solution (GBSS; Gibco BRL, 
Life Technologies Ltd., Paisley, Scotland) supplemented with glucose (6.5 mg/ml) (Merck, 
Darmstadt, Germany), and separated from excess tissue. The slices were then placed on 
semiporous membranes with six slices on each membrane insert (diameter 3 cm; Millipore 
Corp., Bedford, MA, USA), and the inserts transferred to a culture tray (Corning Costar, 
Corning, NY) with six wells, each containing 1 ml of medium consisting of 25% inactivated 
horse serum, 25% Hank´s balanced salt solution (HBSS), and 50% OPTIMEM medium (all from 
Gibco BRL), supplemented with D-glucose (25 mM) and L-glutamine (1 mM). The trays were 
placed in an incubator at 36°C with an atmosphere of 5% CO2 and 95% humidified air. On the 
third day and thereafter the medium was changed to chemically defined serum-free Neurobasal 
  
medium (Gibco BRL), supplemented with D-glucose (25 mM), L-glutamine (1 mM) (Sigma, 
Vallensbæk Strad, Denmark), and 2% B-27 supplement (Gibco. BRL). This medium was 
changed every third or fourth day for 3 weeks before starting the experiments. No antimitotic 
drugs or antibiotics were used at any stage. 
Exposure to excitotoxins and neuropeptide Y agonists/antagonists 
The neurotoxic toxic effects of 2 µM AMPA (Sigma) or 6 µM kainate (Sigma) were first 
examined by exposing slice cultures to these drugs for 24 h, in the culture medium (Neurobasal 
medium, supplemented with D-glucose, L-glutamine, and B-27 supplement). Then, cultures were 
returned to normal medium, without the drugs (Fig. 1). Digital images of the resulting PtdIns 
uptake (see below) were obtained 24 h (day 2) after start of the AMPA or KA exposure, and after 
a 24 h recovery period. In some experiments the cultures from the same batch were exposed to 
AMPA or KA together with 15 µM LY303070, a selective noncompetitive AMPA receptor 
antagonist (kind gift from Lilly Research Laboratories, Indianapolis, IN). The concentrations of 
AMPA and KA used in this work were chose based in previous studies (26, 35). Briefly, 
Kristensen et al. (2001) performed dose-dependent excitotoxic studies of different drugs and 
showed that 3 µM AMPA and 8 µM KA resulted in high levels of PtdIns uptake in the CA1 and 
CA3 pyramidal cell layer, respectively. Moreover, NBQX inhibited AMPA- and KA-induced 
toxicity, with no effect in NMDA-induced toxicity. 
To test the putative neuroprotective role of NPY receptors, the cultures were first pre-incubated 
(24 h) with the selective Y1, Y2, or Y5 receptor agonists (1 µM [Leu31,Pro34]NPY), 300 nM 
NPY1336 or 500 nM NPY(1923)-(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP, respectively) 
(all from Bachem Bubendorf, Switzerland). These concentrations were chose based on previous 
studies performed by us and others (24, 34). After the pre-incubation period, cultures were again 
exposed to the NPY receptor agonists together with 2 µM AMPA or 6 µM KA (Fig. 1). The 
same experimental protocol was used to study the effect of 1 µM BIBP3226 (Peninsula 
Laboratories, Belmont, CA) or 1 µM BIIE0246 (generous gift from Henri Doods, Boehringer 
Ingelheim Pharma, Germany), an Y1 or Y2 receptor antagonist, respectively. Digital images of 
the resulting PtdIns uptake (see below) were obtained after 24 h (day 1) and 48 h (day 2) 
exposure to the NPY receptors agonist and antagonists, as well as after the 24 h recovery period 
in normal medium. Moreover, in order to correct for spontaneous increase in PtdIns 
fluorescence, we subtracted the value for PtdIns uptake at day 0 from the values at day 1, 2, and 
3, and we used the PtdIns values obtained at day 2. 
All experiments included control cultures not subjected to glutamate receptor agonists or NPY 
receptors agonists and antagonists. 
Monitoring propidium iodide uptake 
To quantify neuronal damage, the fluorescent marker propidium iodide (PtdIns, 3,8-diamino-5-
(3-(diethylmethylamino)propyl)-6-phenyl phenanthridinium diiodide; Sigma) was added to the 
medium, in accordance with an earlier established protocol (26, 27). PtdIns is a polar substance 
that enters only dead or dying cells with damaged cell membranes and binds to DNA with a 
brightly red, intensified fluorescence (630 nm), when absorbing blue-green light (493 nm). This 
fluorescent marker is basically nontoxic to neurons (28, 29) and has been used as an indicator of 
  
neuronal membrane integrity (30) and cell damage (29, 31). Three hours before starting the 
experiments, 2 µM PtdIns was added to the medium for determination of basal cellular uptake, 
and this concentration was also used in all subsequent medium changes. PtdIns uptake was 
recorded by fluorescence microscopy [Olympus IMT-2, 4X (Splan FL2)] by using a standard 
rhodamine filter and digital camera (Sensys KAF 1400 G2, Photometrics, Tucson, AZ) with 0.75 
s exposure time. After exposing the cultures to the drugs, digital fluorescent micrographs of the 
cultures were taken at different time points during the experiments (see Fig. 8), for use in 
densitometric measurements of the PtdIns uptake in the dentate granule cell layer (DG), CA3, 
and CA1 pyramidal cell layers. This was performed by delineating the different subfields by 
using NIH Image 1.64 analysis software (National Institutes of Health, Bethesda, MD). 
Morphological preparation and toluidine blue staining 
Organotypic hippocampal slice cultures were prepared and stained as described by Noraberg et 
al. (27). In brief, at the end of each experiment the cultures were fixed for 1 h in 4% phosphate 
buffered paraformaldehyde (PFA; Fluka), washed for 30 min in 0.15 M phosphate buffer, and 
then washed in distilled water for 30 min. After this, a thin and soft brush was used to detached 
and transferred the slices from the membrane, and each culture was placed on glass slides 
(cultures from one well on one glass slide) in a droplet of distilled water and left to dry at 4°C for 
a minimum of 24 h before staining. Then, slices were again washed three times in distilled water; 
stained with the toluidine blue solution (77 mM Na2HPO4,2H2O, 67.2 mM citric acid, 3.3 mM 
toluidine blue) (15 min); dehydrated in 70, 90, and 99% ethanol (2 min each); cleared in xylene 
(5 min); rehydrated in 99 and 96% ethanol and distilled water (2 min each); again stained in 
toluidine blue solution (15 min); rinsed three times in distilled water (5 min each); dehydrated in 
70, 96 and 99% ethanol (0.5, 1.5, and 5 min, respectively); and finally cleared three times (5 min 
each) in xylene and mounted in DePex. The stained cultures were analyzed by optical 
microscopy, under high magnification (×500). 
Data analysis 
The data are expressed as means ± SEM. The values ± SEM are the total number of slices over 
multiple experiments on different days. Statistical significance was determined by using an 
ANOVA, followed by Dunnett´s or Bonferroni´s post-test, as indicated in the figure legends. 
PtdIns uptake values are expressed as percentage of control and in neuroprotection studies the 
PtdIns uptake induced by 2 µM AMPA or 6 µM KA was set to 100%. 
RESULTS 
Protection against AMPA-induced neurodegeneration of dentate granule cells and CA1 
pyramidal cells by NPY receptor activation 
Exposure of hippocampal slice cultures to 2 µM AMPA for 24 h induced an increase in cellular 
uptake of propidium iodide (PtdIns), which was particularly evident in the CA1 pyramidal cell 
layer (214.0±24.6% of control, n=66), and in the dentate granule cell layer (132.1±8.3% of 
control, n=66) (Figs. 2A and 3B). However, the CA3 pyramidal cells did not display a 
corresponding statistically significant increase in the PtdIns uptake (111.1±4.9% of control, 
n=66) (Fig. 2A). Application of a selective AMPA receptor antagonist (LY303070; 15 µM) 
  
allowed us to demonstrate that the neuronal degeneration essentially was due to a selective 
activation of AMPA receptors, since application of this compound abolished the increased PtdIns 
uptake induced by AMPA in the dentate granule cell layer (86.8±3.4%; n=14) and in CA1 
pyramidal cell layer (102.2±16.0%; n=14) (Fig. 2A). 
The putative neuroprotective role of different NPY receptors against AMPA receptor- mediated 
excitotoxicity in dentate granule cells and CA1 pyramidal cells were investigated. In these 
experiments, the mean value of PtdIns uptake in all subfields after 24 h of exposure to 2 µM 
AMPA (n=66) was set to 100%, representing maximal PtdIns uptake (Fig. 2B, 2C, 4A and 4B). 
After pre-exposure (24 h) to the different selective NPY receptors agonists, followed by 24 h of 
co-exposure with 2 µM AMPA, we found that 1 µM [Leu31,Pro34]NPY, an Y1 receptor agonist, 
reduced the PtdIns uptake to 44.9±16.7% (n=18) in the dentate granule cell layer (Fig. 2B), 
without having a statistically significant effect on CA1 pyramidal cells (82.0±10.9%, n=18) (Fig. 
2C). Regarding activation of Y2 receptors, the neuroprotective effect of the selective agonist 
(300 nM NPY1336) was very significant with a reduction of PtdIns uptake to 34.5±20.9% 
(n=19) (Figs. 2B and 3C) in the dentate granule cell layer and 39.0±6.5% (n=19) (Figs. 2C and 
3C) in the CA1 pyramidal cell layer. In the presence of 500 nM NPY(1923)-( 
Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP, known as an Y5 receptor agonist, the AMPA-induced 
PtdIns uptake was reduced to 59.9±12.7% (n=35) in dentate granule cell layer (Fig. 2B), whereas 
no significant inhibition was observed in CA1 pyramidal cell layer (80.5±8.9%, n=35) (Fig. 2C). 
To better characterize the selectivity of the neuroprotective effects mediated by NPY receptors, 
we also tested the effect of Y1 and Y2 receptor antagonists. For the dentate granule cell layer, 
addition of 1 µM BIBP3226 (Y1 receptor antagonist) or 1 µM BIIE0246 (Y2 receptor 
antagonist), essentially abolished the inhibition induced by Y1 (104.7±16.9%, n=21) or Y2 
(82.8±11.1%, n=12) receptor agonists (Fig. 4A). Corresponding to the lack of effect of the NPY 
Y1 receptor agonist in CA1, only the Y2 receptor antagonist BIIE0246 was effective in 
preventing the neuroprotective effect of 300 nM NPY1336 (93.2±1.9%, n=12) (Fig. 4B). 
Cultures exposed to 2 µM AMPA for 24 h, followed by 24 h recovery, also showed a significant 
neurodegeneration when evaluated by toluidine blue staining, in particular in the CA1 pyramidal 
cells, where neurons with apoptotic-like morphology were found. Indeed, it was possible to 
observe cell shrinkage and nuclear condensation (Fig. 5B), which was prevented in the presence 
of the Y2 receptor agonist (NPY1336) (Fig. 5C). 
Protection against kainic acid-induced neurodegeneration of CA3 and CA1 pyramidal cells 
by NPY receptor activation 
As previously reported, the toxicity induced by 6 µM kainate followed a different pattern from 
that observed in the presence of 2 µM AMPA (26, 35). Exposure of hippocampal slice cultures 
to 6 µM kainate for 24 h induced PtdIns uptake in the CA1 (122.6±12.8% of control, n=33) and 
in particular in the CA3 (161.4±12.7% of control, n=33) pyramidal cell layer, whereas no 
increase PtdIns uptake was found in the dentate granule cell layer (105.1±4.4%, n=33) (Figs. 6A 
and 7B). The neurodegeneration in CA1 and CA3 was clearly mediated by kainate receptors, 
since 15 µM of the AMPA receptor antagonist, LY303070, was unable to significantly prevent 
the PtdIns uptake induced by 6 µM kainate in both cell layers (131.0±5.5% and 138.8±17.0% of 
control, respectively; n=14) (Fig. 6A). 
  
In accordance with the neuroprotective effect mediated by Y2 receptors against AMPA-induced 
toxicity, in CA only activation of Y2 receptors inhibited the kainic acid-induced PtdIns uptake 
(76.6±4.8%, n=35) (Fig. 6B; 6 µM kainate-induced PtdIns uptake set to 100%). In contrast, 
selective activation of Y1, Y2, and Y5 receptors prevented the increase in the kainic acid-
induced PtdIns uptake in the CA3 pyramidal cell layer (Fig. 6C). Exposure to 1 µM 
[Leu31,Pro34]NPY, 300 nM NPY1336 or 500 nM NPY(1923)- 
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP reduced the kainic acid-induced PtdIns uptake to 
67.8±13.4% (n=21), 64.4±3.5% (n=35) or 62.7±3.6% (n=18), respectively (Figs. 6C, 7C, and 
7D). 
Evaluation of the cultures exposed to 6 µM kainate for 24 h followed by 24 h recovery by 
toluidine blue staining (Fig. 8B) indicated strong degenerative changes, especially in the CA3 
pyramidal cell layer, where swollen neurons with a necrotic-like morphology were observed 
(Fig. 8B). Also, these structural changes were prevented in the presence of the Y2 receptor 
agonist (NPY1336) (Fig. 8C). 
DISCUSSION 
Using organotypic slice cultures of rat hippocampus, we investigated the putative 
neuroprotective role of NPY receptors against excitotoxic glutamate receptor mediated 
neurodegeneration and found that NPY Y1, Y2, and Y5 receptors played a neuroprotective role 
in AMPA and kainic acid-induced neuronal cell death. 
AMPA and kainate-induced excitotoxicity 
The excitotoxic effect caused by activation of ionotropic glutamate receptors has been studied in 
various in vivo (34) and in vitro models (35, 29). In agreement with previous studies, we 
observed that hippocampal slice cultures treated with AMPA (2 µM) or kainate (6 µM) display 
selective degeneration of CA1 (28) or CA3 pyramidal cells (36), respectively. Indeed, previous 
reports demonstrated that the CA3 subregion is particularly rich in receptors with high affinity to 
kainate (37), and that these receptors are involved in CA3 pyramidal cell degeneration under 
excitotoxic conditions (37, 38). However, in several models, the pharmacological dissection of 
active AMPA and kainate receptors was complicated by the similar agonist activity of AMPA 
and kainate at both receptors. Using a noncompetitive antagonist of AMPA receptors, 
GYKI53655, it was possible to unmask functional activity of kainate receptors (39). In the 
present work, the selective involvement of AMPA and kainate receptors in the excitotoxicity 
caused by AMPA or kainate was investigated further by pretreating the cultures with LY303070, 
an AMPA receptor antagonist [(-) enantiomer of GYKI53655]. We observed that the PtdIns 
uptake induced by AMPA (2 µM) was completely prevented in the presence of LY303070. In 
slice cultures treated with kainate (6 µM), LY303070 did not, however, significantly prevent the 
kainate-induced toxicity, suggesting that the toxicity mediated by 2 µM AMPA or 6 µM kainate 
was due to selective activation of AMPA or kainate receptors, respectively. 
A previous work from our laboratories has already extensively characterized the excitotoxic 
profiles of AMPA, KA, and NMDA in organotypic hippocampal slice cultures (28). The authors 
showed that even high concentrations of MK-801 (10 µM), an NMDA receptor antagonist, did 
not protect against the degeneration caused by 3 µM AMPA or 8 µM KA (28), indicating that the 
  
PtdIns uptake observed in these conditions, was not mediated by NMDA receptors. Moreover, 
long-term exposure to AMPA induces substantial neuronal death involving apoptotic-like 
morphology (40), while kainic acid-induced seizures result in necrotic-like cell death (41). Our 
results are in accordance with these studies, since the morphology observed after treating the 
cultures with AMPA or kainate, respectively, also shows similar cell death patterns (Figs. 5 and 
8). However, a clear distinction between patterns of cell death need more refined methods and is 
complicated by the variety of mechanism involved during an excitotoxic insult (42). Exposure of 
neurons to excitotoxins predominantly induced apoptosis or necrosis, and this appears to depend 
on the duration and intensity of exposure (42). 
Neuroprotection by NPY receptor activation 
Several studies show that NPY can inhibit epileptiform activity in the rat hippocampus (24). 
Moreover, epileptic seizures result in extensive increase in extracellular glutamate and NPY 
mRNA expression (19), indicating that NPY-mediated effects may be activated under 
epileptogenesis and excitotoxicity. In this study, we further investigated the putative 
neuroprotective role of NPY receptor activation during hyperactivation of AMPA and kainate 
receptors in organotypic hippocampal slice cultures. In dentate granule cell layer, activation of 
Y2 receptors played the most important neuroprotective role when compared with both Y1 and 
Y5 receptors. This corresponds with our previous findings that Y2 receptor activation inhibits 
glutamate release in this subregion (23), despite a relatively lower expression of these receptors 
(11). Other studies have shown that NPY inhibits glutamatergic excitation in the rat dentate 
gyrus (43) and in epileptic human dentate gyrus (44). Activation of Y1 and Y5 receptors is also 
neuroprotective for dentate granule cells in accordance with other studies (15, 18, 45). Moreover, 
McQuiston et al. (46) reported that Y1 receptors inhibit N-type Ca2+ currents in granular cells, 
whereas we previously have reported that these receptors inhibit glutamate release in dentate 
gyrus synaptossomes (23). In rat neocortical neurons, Bacci et al. (47) showed that NPY elicits a 
long-lasting decrease in evoked EPSCs and decrease evoked monosynaptic IPSCs in GABAergic 
interneurons, which suggest that this neuropeptide has differential effects on different neuronal 
subtypes. 
Concerning the role of NPY Y5 receptors, Marsh et al. (18) used Y5R-deficient mice to 
demonstrate that Y5 receptors were involved in mediating NPY´s inhibitory actions in the mouse 
hippocampus. Recently, Cabrele et al. (7) developed the first Y5 receptor-selective agonist, and 
by using this we identified a specific Y5 receptor-like neuroprotection of dentate granule cells 
and CA3 pyramidal cells in the present study. In CA1, we only observed significant 
neuroprotective effects mediated by the activation of Y2, but not Y1 or Y5 receptors. This is 
consistent with our previous findings that selective activation of Y1 receptors did not modulate 
the release of glutamate in CA1 (23). However, in agreement with our glutamate release studies, 
this does not mean that Y1 or Y5 receptors are not active in CA1, but only suggests that they do 
not have a significant neuroprotective role in this subregion. Indeed, the distribution of mRNA 
for NPY receptors is not necessarily indicative of the distribution of the expressed proteins or 
binding sites. For example, there is for the Y5 receptor a clear lack of correlation between Y5 
mRNA levels and binding sites in the human hypothalamus (48). 
When kainate was applied as the excitotoxin, it mainly induced cell death in the CA3 pyramidal 
cell layer, and activation of Y1, Y2, or Y5 receptors was again neuroprotective. For the kainate-
  
induced toxicity in CA1, only the Y2 receptor was neuroprotective. For CA3, we have 
previously reported that activation of Y1 and Y2 receptors inhibits glutamate release in a very 
similar way (23), just as Y5 receptors have been shown to mediate presynaptic inhibition of 
stratum radiatum-evoked glutamatergic responses in some CA3 neurons (45). 
Under normal conditions, NPY is expressed only by GABAergic interneurons, but during 
excitotoxic conditions, the expression of NPY and different NPY receptors is increased (19, 20). 
Moreover, Van den Pol and collaborators (49) have demonstrated that glutamate-dependent 
activity is necessary for NPY to depress the intracellular Ca2+ concentration and the electrical 
activity of neurons. Given that NPY affects synaptic transmission and neuronal excitability, and 
that this effect is significantly mediated by its interaction with glutamatergic neurotransmission 
(3), we found important to clarify the involvement of different NPY receptors in the protection 
against excitotoxicity. 
Along this study, we have demonstrated for the first time the neuroprotective action of Y1, Y2, 
and Y5 receptors against AMPA and kainate mediated neurodegeneration in different 
hippocampal subregions. Such knowledge of which NPY receptors mediate the actions of NPY 
in the dentate granule cell layer, CA1 and CA3 pyramidal cell layers may be important for 
pharmacological targeting in several pathologic conditions associated with glutamate receptor 
hyperactivation as dysfunction. 
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Figure 1. Experimental protocol for investigating the potential neuroprotective effects of neuropeptide Y 
receptors in hippocampal slice cultures. Propidium iodide (PtdIns) was used as a marker for cell death. Donor tissue: P7 
hippocampus. For details, see text. 
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Figure 2. AMPA-induced cell degeneration in the dentate granule cell layer and CA1 pyramidal cell layer, and 
neuroprotection by NPY receptor activation. A) Densitometric measurements of propidium iodide (PtdIns) uptake 
induced by 2 µM AMPA in dentate granule cell layer (DG), CA1 and CA3 pyramidal cell layers, and effect of LY303070 
(15 µM) on the toxicity induced by AMPA in both dentate granule cell layer and CA1 pyramidal cell layer. Effect of Y1 
(1 µM [Leu31,Pro34]NPY), Y2 (300 nM NPY13–36), or Y5 receptor agonist (500 nM NPY(19–23)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP) on the PtdIns uptake induced by 2 µM AMPA in (B) the dentate granule cell 
layer or (C) CA1 pyramidal cell layer. In (A) the PtdIns uptake determined after 24 h is expressed as a percentage of 
control. In (B) and (C) the PtdIns uptake induced by 2 µM AMPA was set to 100%. Data are shown as means ± SEM with 
n=14–66. A) ++P<0.01, +++P<0.001 using t-test for comparison with control (no drugs exposure), and **P<0.01, 
***P<0.001 using ANOVA with Bonferroni correction for comparison with the effect of 2 µM AMPA in DG and CA1, 
respectively. B, C) *P<0.05, ***P<0.001 using Dunnett´s correction for comparison with control (2 µM AMPA). 
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Figure 3. Fluorescent microscope digital images of PtdIns uptake in hippocampal cultures derived from 7-day-old 
rats and grown for 3 weeks. A) Control culture with low basal PtdIns uptake. B) Culture exposed to 2 µM AMPA with 
increase in PtdIns uptake in the CA1 pyramidal cell layer. Culture co-exposed to (C) 2 µM AMPA and 300 nM NPY13–
36 (Y2 receptor agonist) or to (D) 2 µM AMPA and 1 µM NPY (endogenous NPY receptor agonist). Scale bar, 500 µm. 
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Figure 4. Blockade of Y1 or Y2 receptor-mediated neuroprotection by selective antagonists of the receptors 
subtypes. Effect of 1 µM BIBP3226 or 1 µM BIIE0246, the Y1 or Y2 receptor antagonist, respectively, on the PtdIns 
uptake induced by 2 µM AMPA plus Y1 or Y2 receptor agonist in (A) the dentate granule cell layer or (B) CA1 
pyramidal cell layer. The PtdIns uptake induced by AMPA was set to 100%. Data are shown as mean ± SEM, with n = 12–
21 and *P<0.05, ***P<0.001 by using Dunnett´s correction for comparison with control (2 µM AMPA). 
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Figure 5. Evaluation of the morphological changes of CA1 pyramidal cells after an excitotoxic insult with AMPA, 
in the absence or in the presence of an Y2 receptor agonist. A) Toluidine blue-stained 3-week-old hippocampal slice 
culture in a control situation. Cultures exposed to (B) 2 µM AMPA for 24 h, followed by 24 h recovery, or to (C) 2 µM 
AMPA plus 300 nM NPY13–36 for 24 h, followed by 24 h recovery (pre-incubation with NPY13–36 during 24 h). B) 
The CA1 pyramidal cells displayed degenerative features with darkly stained nuclei, which are not frequently found in 
(A) control situation or in (C) the presence of the Y2 receptor agonist. Arrows indicate apoptotic-like neurons. High 
magnification of the CA1 pyramidal cell layer (×500). Scale bar, 25 µm. 
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Figure 6. Kainate-induced cell degeneration in the CA1 and CA3 pyramidal cell layers and neuroprotection by 
NPY receptor activation. A) Densitometric measurements of propidium iodide (PtdIns) uptake induced by 6 µM KA in 
dentate granule cell layer (DG), CA1 and CA3 pyramidal cell layers, and effect of LY303070 (15 µM) on the toxicity 
induced by kainate in CA1 and CA3 pyramidal cell layers. B, C) Effect of Y1 (1 µM [Leu31,Pro34]NPY), Y2 (300 nM 
NPY13–36) or Y5 receptor agonist (500 nM NPY(19–23)-(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP) on the PtdIns 
uptake induced by 6 µM KA in (B) CA1 and (C) CA3 pyramidal cell layers. In A) the PtdIns uptake recorded after 24 h is 
expressed as a percentage of control. In (B and C) the PtdIns uptake induced by kainate was set to 100%. Data are shown 
as mean ± SEM with n = 18–33. A) +P<0.05, ++P<0.01 by using t-test for comparison with control (no drugs exposure).  
B, C) *P<0.05 by using Dunnett´s correction for comparison with control (6 µM KA). 
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Figure 7. Fluorescent microscope digital images of propidium iodide (PtdIns) uptake in hippocampal cultures 
derived from 7-day-old rats and grown for 3 weeks. A) Control culture with low basal PtdIns uptake. B) Culture 
exposed to 6 µM KA with increase in PtdIns uptake in the CA3 pyramidal cell layer. Culture with clearly inhibited PtdIns 
uptake after co-exposure to (C) 6 µM KA and 300 nM NPY13–36 (Y2 receptor agonist) or to (D) 6 µM KA and 1 µM 
NPY (endogenous NPY receptor agonist). Scale bar, 500 µm. 
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Figure 8. Morphological characteristics of CA3 pyramidal cells after an excitotoxic insult with KA in the absence 
or in the presence of an Y2 receptor agonist. A) Toluidine blue stained 3-week-old hippocampal slice culture in a 
control condition. Cultures exposed to (B) 6 µM KA for 24 h, followed by 24 h recovery, or to (C) 6 µM KA plus 300 nM 
NPY13–36 for 24 h, followed 24 h recovery (pre-incubation with NPY13–36 during 24 h). In (B) some of the CA3 
pyramidal cells show a necrotic- (arrowhead) or apoptotic-like morphology (arrows), which are not frequently found in 
(A) control situation or in (C) the presence of NPY13–36. High magnification of the CA3 pyramidal cell layer (×500). 
Scale bar, 25 µm. 
